 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | S62798 / Servier
Preclinical, Journal: S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism. (Pubmed Central) - Aug 4, 2021
In vivo, curative S62798 intravenous treatment, alone or associated with heparin, accelerated clot lysis by potentiating endogenous fibrinolysis and thus decreased pulmonary fibrin clots. S62798 is expected to be a therapeutic option for pulmonary embolism patients on top of anticoagulants.
- S62798 / Servier
[VIRTUAL] S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism () - Jul 30, 2020 - Abstract #ESC2020ESC_537;
Due to its capacity to enhance endogenous fibrinolysis, S62798, which has completed phase I studies, is expected to be a therapeutic option for intermediate high risk PE patients on top of anticoagulants. With early recanalization, S62798 should rapidly reduce pulmonary artery pressure and resistance, with concomitant improvement in right ventricular function, preserving cardiac function, and reducing acute PE-related morbidity and mortality in these patients.
- S62798 / Servier
[VIRTUAL] Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects () - Jul 30, 2020 - Abstract #ESC2020ESC_493;
S62798, a potent TAFIa inhibitor, has a favourable safety profile with a linear PK. PD results on TAFIa inhibition and clot lysis assay suggest that S62798 has relevant properties to pursue clinical development as an enhancer of endogenous fibrinolysis for the treatment of thromboembolic diseases
- ||||| S62798 / Servier
New P2 trial: A study to find the appropriate dose of S62798 to treat patients with pulmonary circulation blocked by a clot (EUDRACT) - Apr 21, 2020
P2, N=370, Ongoing, Sponsor: Institut de Recherches Internationales Servier